News

News

December 8, 2009

Immunomedics reports updated results of subcutaneous humanized anti-CD20 antibody therapy of lymphoma with Veltuzumab

December 7, 2009

Immunomedics announces preclinical results of Milatuzumab in B-cell malignancies

December 7, 2009

Follow-up results of two clinical studies with Veltuzumab and Epratuzumab reported at ASH

December 2, 2009

Immunomedics announces outcome of 2009 annual meeting of stockholders

November 30, 2009

Immunomedics to present at 51st ASH annual meeting

November 6, 2009

Immunomedics announces first quarter fiscal 2010 results and clinical program developments

October 23, 2009

Immunomedics receives corporate award from New Jersey Inventors Hall Of Fame

October 23, 2009

Immunomedics receives corporate award from New Jersey Inventors Hall Of Fame

October 19, 2009

Immunomedics awarded three grants by NIH to develop new agents for imaging and therapy of cancer

October 15, 2009

Further topline results for Epratuzumab phase IIb study in Systemic Lupus Erythematosus (SLE)

August 27, 2009

Immunomedics announces fiscal 2009 results

August 27, 2009

UCB and Immunomedics announce positive results for Epratuzumab Phase IIb study in Systemic Lupus Erythematosus (SLE)

July 24, 2009

Immunomedics partners with Alexis Biotech to develop targeted vaccines in cancer and AIDS

July 21, 2009

Immunomedics announces U.S. patent for a facile method of Fluorine-18 labeling of proteins and peptides

June 17, 2009

Immunomedics reports improved efficacy with combination Veltuzumab and pretargeted anti-CD20 radioimmunotherapy in lymphoma model

June 16, 2009

Immunomedics reports new antibody for pretargeted imaging and therapy of colorectal cancer

June 15, 2009

Immunomedics reports improved F-18 labeling of peptides for pet imaging of tumors

June 15, 2009

Immunomedics reports updated Phase II results with radiolabeled Epratuzumab in non-Hodgkin’s lymphoma

June 8, 2009

Immunomedics to present at the Society of Nuclear Medicine 56th annual meeting

June 5, 2009

Immunomedics reports updated results of low-dose Veltuzumab for Immune Thrombocytopenic Purpura

June 1, 2009

Immunomedics reports first efficacy results of subcutaneous humanized anti-CD20 antibody therapy of lymphoma with Veltuzumab

May 31, 2009

Novel targeted radiation therapy from Immunomedics produces objective responses in pancreatic cancer

May 30, 2009

Immunomedics reports updated results of Milatuzumab in dose-escalation study for multiple myeloma

May 19, 2009

Immunomedics announces two new patent awards

May 18, 2009

Final therapy and safety results from phase I/II study of Veltuzumab, a second-generation anti-CD20 humanized antibody, published

May 18, 2009

Results of novel radiolabeling method for pet imaging published by Immunomedics

May 15, 2009

Final results with Epratuzumab in combination with Rituximab and chemotherapy in patients with aggressive lymphoma being reported in an oral presentation at ASCO

May 11, 2009

Immunomedics announces clinical updates third quarter fiscal 2009 results

May 5, 2009

Immunomedics announces U.S. patent for dock-and-lock

Apr 22, 2009

Immunomedics reports results that could expand use of Milatuzumab in cancer therapy

April 22, 2009

Immunomedics reports preclinical results of novel protein constructs from dock-and-lock

April 13, 2009

Immunomedics to report progress with product candidates at aacr 100th annual meeting 2009

February 9, 2009

Immunomedics announces second quarter fiscal 2009 results

February 5, 2009

immunomedics hPAM4 receives fda fast track designation for pancreatic cancer therapy

January 29, 2009

Immunomedics reports properties and structure-function relationships of Veltuzumab

January 20, 2009

Immunomedics announces preclinical therapy results of SN-38 immunoconjugate for colorectal cancers

January 7, 2009

Immunomedics to present at 27th annual JP Morgan conference meeting